By Monalisa Breazu, Learning & Development Administrator, One Nucleus
News
Cambridge, UK, April 25, 2024, Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics. The next-generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early-phase development.
To help address logistical challenges and provide supply chain advice to the life science community, Biocair has launched a roadshow to deliver on-site support at a variety of science parks across the UK.
The event series aims to support the vital role logistics plays in ensuring the safe, efficient transportation of invaluable life science materials. Biocair is facilitating this by meeting with industry representatives and providing a physical presence with this open, flexible approach to customer service.
World-leading contract research organization Sygnature Discovery has announced a major new hire to its leadership team, with the appointment of Dr David Witty as Chief Scientific Officer (CSO) to ensure its integrated drug discovery capabilities remain at the cutting edge of the industry.
David will be responsible for ensuring Sygnature Discovery remains globally recognised for the quality of its scientific operations and is able to attract the top scientific talent in the industry.
It can be challenging to hit your milestones and goals when macroeconomic conditions continue to evolve and change. More than ever, you need to optimise your spend, scale up efficiently, maximise productivity, whilst reducing your environmental impact.
At Thermo Fisher Scientific, we provide you with trusted life science solutions that can enable you to get the most from your resources and help bridge gaps so you can meet your milestones quickly.
This event brought together life science experts and entrepreneurs to explore what should be done to make the UK a scale-up market of choice. The event included a Keynote by George Freeman, MP and a panel discussion, moderated by Lord O’Shaughnessy. The event helped to raise awareness on what factors influence a companies’ decision on where to locate and what policies, investment and other changes can ensure the UK is as attractive and internationally competitive as possible.
- Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively
- Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
• Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer
• Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions
• Data demonstrated Macomics’ ENIGMAC™ platform at-scale CRISPR screening for macrophage target discovery
Access to compound collection enables greater flexibility and efficiencies in screening and target identification
Cambridge, UK and Kyiv, Ukraine, 11th April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.